Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.46 |
| ▸ | CPT2 | P23786 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26056411 | 0.82 | ACLY (0.46) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL4442944 | 0.76 | SLC22A6 (0.43) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL11507546 | 0.74 | ALDH1A1 (0.43) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL10940349 | 0.74 | HMGCR (0.50) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL11111132 | 0.74 | ACLY (0.40) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL5793304 | 0.74 | ACLY (0.45) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL10520915 | 0.72 | TDP1 (0.43) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL10779877 | 0.71 | PGD (0.39) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL19383705 | 0.69 | HMGCR (0.44) | ACLYCPT2ALDH1A1HMGCRCHRM1 | |
| SCHEMBL6338152 | 0.69 | HMGCR (0.44) | ACLYCPT2ALDH1A1HMGCRCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| WO-2011109294-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20170129853-A1 | Carbondisulfide Derived Zwitterions | TPAT IP LLC | 2017-05-11 | — | — | US | disclosed |
| US-9580385-B2 | Carbondisulfide derived zwitterions | TPAT IP LLC | 2017-02-28 | — | — | US | disclosed |
| US-9320798-B2 | Lipid delivery formulations | DICERNA PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2011109294-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129853-A1 | Carbondisulfide Derived Zwitterions | SRM, PKD1, SLC7A11 | ACLY 2542/4885CPT2 3384/4885ALDH1A1 4270/4885 |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | LIPA, LIPC, CETP | ACLY 1490/4885CPT2 210/4885ALDH1A1 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.